Pharma firms deal with clinical trial complexity

A draft guidance on multi-regional clinical trials would make it harder for pharmaceutical companies to get innovative drugs approved in the PRC. If implemented, the new rules could lead to confusion and delays

4 minute readDecember 05, 2014 at 06:53 AM

clpstaff

& clp articles

The China Food and Drug Administration (CFDA)'s draftGuidance on Multi-Regional Clinical Trials (MRCTs) raises the requirements for MRCTs, spurring concern at foreign pharmaceutical companies over potential problems with the

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)